New obesity drug AZD4144 enters human testing
NCT ID NCT06942923
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage study tested a new drug called AZD4144 in 28 adults with obesity to see if it is safe and how it affects inflammation markers in the blood. Participants took either the drug or a placebo daily for a short time. The goal was to check for side effects and measure changes in certain inflammatory substances, like interleukin-6. This is a first step in humans, so results will show whether the drug is safe enough for larger studies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- AZD4144
- What this could lead to
- If it works, this could point toward a treatment for obesity that also reduces inflammation.
- What could go wrong
- This is a very early Phase 1 trial with only 28 participants, so it is primarily checking safety, not effectiveness. The drug may not work or could have side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Berlin, 14050, Germany
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common antifungal change how an experimental drug acts?
- Can a new injection help tackle obesity? a safety trial begins
- Will a new pill formula absorb the same? a trial puts it to the test
- Can a new drug tame Alzheimer's? early trial aims to find out
- Could sitting too much alter your nervous system?
- Could a cancer drug alter Metformin's effects? a trial investigates